BOLT biotech catalysts & pipeline

BOLT BIOTHERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

PRA-216 — Clinical data readout

Q2 2027

Phase 2 development in asthma, COPD, and atopic dermatitis has been initiated, with a Phase 2 study in EoE planned, and with patient data from all four trials expected beginning in the second quarter of 2027 and continuing through the fourth quarter of 2027.

Source filing

IL-31 containing bispecific antibody — Clinical data readout

H2 2027

First-in-human studies in healthy volunteers and patients are expected to begin in the second half of 2027, with clinical data also expected in the second half of 2027.

Source filing

BDC-4182 — Initial data

Q3 2026

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results

Source filing

Explore the free biotech catalyst calendar